← Hercules Capital overview
Hercules Capital, Inc.HTGC

Why is Hercules Capital (HTGC) moving?

Q3 2026
▲2

Hercules Delivers Record Quarter, Raises Payout, Keeps Funding Growth

  • Record Q2 results and dividend increase Hercules reported record second-quarter originations, revenue of $149.1 million and net income of $130.2 million, and raised its regular quarterly dividend to $0.47 plus a $0.07 supplemental payout. Strong earnings and more cash returned to shareholders support the stock.

    This is the core positive fundamental driver of the period.

  • Two large note offerings raise debt costs Hercules priced $325 million of 6.300% notes due 2031 and an upsized $400 million of 6.70% notes due 2029, mainly to repay existing borrowings and fund investments. More debt at higher rates lifts interest expense, but extends maturities and supports lending capacity.

    These financings are the main capital-structure events and carry both risk and benefit.

  • New and expanded loan commitments Hercules provided a $50 million term loan to Dyne Therapeutics with options for more, and is part of the debt financing for Capitolis' $220 million raise. New commitments generate fee income and grow the portfolio, though they also add credit exposure.

    Shows the origination pipeline that powers Hercules' earnings.

  • Analyst estimates point to flat near-term EPS Ahead of earnings, analysts expect $0.49 per share, flat versus a year ago, on revenue of $142.2 million. The stock slipped 1.25% that day and carries a Hold rank, a reminder that growth may pause even after a strong quarter.

    Provides the main counterweight to the bullish record-quarter narrative.

August 2026
▲2

Hercules Delivers Record Quarter, Raises Payout, Keeps Funding Growth

  • Record Q2 results and dividend increase Hercules reported record second-quarter originations, revenue of $149.1 million and net income of $130.2 million, and raised its regular quarterly dividend to $0.47 plus a $0.07 supplemental payout. Strong earnings and more cash returned to shareholders support the stock.

    This is the core positive fundamental driver of the period.

  • Two large note offerings raise debt costs Hercules priced $325 million of 6.300% notes due 2031 and an upsized $400 million of 6.70% notes due 2029, mainly to repay existing borrowings and fund investments. More debt at higher rates lifts interest expense, but extends maturities and supports lending capacity.

    These financings are the main capital-structure events and carry both risk and benefit.

  • New and expanded loan commitments Hercules provided a $50 million term loan to Dyne Therapeutics with options for more, and is part of the debt financing for Capitolis' $220 million raise. New commitments generate fee income and grow the portfolio, though they also add credit exposure.

    Shows the origination pipeline that powers Hercules' earnings.

  • Analyst estimates point to flat near-term EPS Ahead of earnings, analysts expect $0.49 per share, flat versus a year ago, on revenue of $142.2 million. The stock slipped 1.25% that day and carries a Hold rank, a reminder that growth may pause even after a strong quarter.

    Provides the main counterweight to the bullish record-quarter narrative.

Latest
▲2

Hercules Delivers Record Quarter, Raises Payout, Keeps Funding Growth

  • Record Q2 results and dividend increase Hercules reported record second-quarter originations, revenue of $149.1 million and net income of $130.2 million, and raised its regular quarterly dividend to $0.47 plus a $0.07 supplemental payout. Strong earnings and more cash returned to shareholders support the stock.

    This is the core positive fundamental driver of the period.

  • Two large note offerings raise debt costs Hercules priced $325 million of 6.300% notes due 2031 and an upsized $400 million of 6.70% notes due 2029, mainly to repay existing borrowings and fund investments. More debt at higher rates lifts interest expense, but extends maturities and supports lending capacity.

    These financings are the main capital-structure events and carry both risk and benefit.

  • New and expanded loan commitments Hercules provided a $50 million term loan to Dyne Therapeutics with options for more, and is part of the debt financing for Capitolis' $220 million raise. New commitments generate fee income and grow the portfolio, though they also add credit exposure.

    Shows the origination pipeline that powers Hercules' earnings.

  • Analyst estimates point to flat near-term EPS Ahead of earnings, analysts expect $0.49 per share, flat versus a year ago, on revenue of $142.2 million. The stock slipped 1.25% that day and carries a Hold rank, a reminder that growth may pause even after a strong quarter.

    Provides the main counterweight to the bullish record-quarter narrative.